Faculty Information - TACHIBANA Hidekazu

（Last updated : 2026-05-14 13:25:52）

TACHIBANA Hidekazu
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position

■ Published papers

1.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
2.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
3.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
4.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
5.	Original article	Effects of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. 2023/10
6.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
7.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
8.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
9.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
10.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
11.	Original article	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. 2023/03
12.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
13.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
14.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
15.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
16.	Original article	New longitudinal component of the RENAL nephrometry score for predicting the operative complexity in transperitoneal robot-assisted partial nephrectomy. 2022/06
17.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
18.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
19.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
20.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
21.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
22.	Original article	Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. 2021/12
23.	Original article	Greater renal function benefit from enucleation technique for more complex renal tumors in robot-assisted partial nephrectomy. 2021/10
24.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
25.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
26.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
27.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
28.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
29.	Original article	Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
30.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
31.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
32.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
33.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
34.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
35.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
36.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
37.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
38.	Case report	Multiple myeloma with testicular involvement: A case report. 2019/09
39.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
40.	Original article	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. 2019/08
41.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
42.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
43.	Original article	Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
44.	Original article	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
45.	Original article	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
46.	Original article	Robot-assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity score-matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. 2018/04
47.	Original article	Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. 2017/12
48.	Original article	Impact of preoperative proteinuria on renal functional outcomes after open partial nephrectomy in patients with a solitary kidney. 2017/11
49.	Original article	Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. 2017/07
50.	Original article	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. 2016/10
51.	Original article	Association between body mass index and outcomes in Japanese living kidney transplant recipients: The role of sex differences. 2016/09
52.	Original article	The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava 2016/02
53.	Other	Possible impact of continuous drainage after minimally invasive partial nephrectomy. 2015/11
54.	Case report	Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. 2015/08
Display 5 items
Display all(54)

■ Academic conference presentation

1.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
2.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
3.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
4.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
5.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
6.	Effect of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. （Poster notice） 2023/04/21
7.	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. （Speech，General） 2023/04/20
8.	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. （Speech） 2023/04/20
9.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
10.	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. （Poster notice，General） 2022/05/16
11.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
12.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
13.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
14.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
15.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2020/12/23
16.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2020/12/23
17.	Safety and efficacy of nivolumab for patients with chronic kidney disease. （Speech，General） 2020/12/23
18.	Therapeutic benefit of lymphadenectomy during radical nephroureterectomy for elderly patients with upper tract urothelial carcinoma. （Speech，General） 2020/12/23
19.	Reduced risk of new occurrence or progression of sarcopenia by robot-assisted radical cystectomy compared to the open procedure. （Speech，General） 2020/12/22
20.	Clinical relevance of immunoglobulin M deposition in peritubular capillaries in ABO-incompatible kidney transplantation. （Poster notice，General） 2020/05/30
21.	The relationship between metformin and post-operative recurrence of renal cell carcinoma （Poster notice，General） 2019/10/24
22.	Immunoglobulin deposition in peritubular capillaries in ABO-incompatible kidney Transplantation （Speech，General） 2019/10/02
23.	Robot-assisted partial nephrectomy is superior in terms of postopetive acute kidney injury,as compared to open partial nephrectomy （Poster notice，General） 2019/05/04
24.	Association of immune-related adverse events with prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2019/05/03
25.	Safety and impact on renal function of nivolumab use for patients with chronic kidney disease and end stage renal disease in metastatic renal cell carcinoma. （Speech，General） 2018/08/18
26.	Effect of early-period relative dose intensity in first-line sunitinib therapy with a 2-weeks-on and 1-week-off regimen for metastatic renal cell carcinoma. （Poster notice，General） 2018/05/20
27.	Predictive factors for immediate progression after nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2018/04/20
28.	Analysis of predictive factors associated with prolonged operative time during robot-assisted partial nephrectomy （Poster notice，General） 2017/05/14
29.	The Superior Preservation of Postoperative Renal Function in Robotic Partial Nephrectomy,Compared with the Laparoscopic Procedure,is Associated with Less Parenchymal Volume Loss,Not Shorter Renal Ischemia Time:A Propensity Score-Matched Analysis （Poster notice，General） 2017/05/14
30.	Impact of surgeon's experience on occurrence of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2016/11/11
31.	Association of preoperative proteinuria with renal functional outcomes after open partial nephrectomy in patients with an anatomically or functionally solitary kidney. （Poster notice，General） 2016/05/08
32.	Comparison of perioperative outcomes with or without renorrhaphy in open partial nephrectomy: A propensity score-matched study. （Poster notice，General） 2016/05/08
33.	Better preservation of renal function after robotic partial nephrectomy is associated with lower volume loss compared with laparoscopic partial nephrectomy. （Speech） 2016/04/25
34.	Comparison of perioperative outcomes with or without renorrhaphy in open partial nephrectomy: A propensity score-matched study. （Poster notice，General） 2016/03/14
35.	Association between better renal function preservation and lower volume loss between robotic partial nephrectomy and laparoscopic partial nephrectomy: A propensity score matched analysis. （Poster notice，General） 2016/03/13
Display 5 items
Display all(35)

■ Education

2020/09/20
Degree Acquisition

Tokyo Women's Medical University,